CN115215764B - Preparation method of deuterated aromatic nitrile compound - Google Patents
Preparation method of deuterated aromatic nitrile compound Download PDFInfo
- Publication number
- CN115215764B CN115215764B CN202210812275.XA CN202210812275A CN115215764B CN 115215764 B CN115215764 B CN 115215764B CN 202210812275 A CN202210812275 A CN 202210812275A CN 115215764 B CN115215764 B CN 115215764B
- Authority
- CN
- China
- Prior art keywords
- deuterated
- aromatic nitrile
- deuteration
- compound
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 deuterated aromatic nitrile compound Chemical class 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000003054 catalyst Substances 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 15
- 229910052751 metal Inorganic materials 0.000 claims abstract description 13
- 239000002184 metal Substances 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 229910052805 deuterium Inorganic materials 0.000 claims abstract description 11
- 239000007800 oxidant agent Substances 0.000 claims abstract description 11
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 10
- 238000011065 in-situ storage Methods 0.000 claims abstract description 10
- 239000012298 atmosphere Substances 0.000 claims abstract description 9
- 230000003197 catalytic effect Effects 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 230000001590 oxidative effect Effects 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- 230000007062 hydrolysis Effects 0.000 claims abstract description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052748 manganese Inorganic materials 0.000 claims description 7
- 239000011572 manganese Substances 0.000 claims description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 6
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 claims description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 5
- 239000005708 Sodium hypochlorite Substances 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical group [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 3
- 229910052786 argon Inorganic materials 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 229940071125 manganese acetate Drugs 0.000 claims description 3
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 claims description 3
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 229930192474 thiophene Natural products 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical class C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 3
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 3
- JHWIEAWILPSRMU-UHFFFAOYSA-N 2-methyl-3-pyrimidin-4-ylpropanoic acid Chemical compound OC(=O)C(C)CC1=CC=NC=N1 JHWIEAWILPSRMU-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 229910021503 Cobalt(II) hydroxide Inorganic materials 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- ASKVAEGIVYSGNY-UHFFFAOYSA-L cobalt(ii) hydroxide Chemical compound [OH-].[OH-].[Co+2] ASKVAEGIVYSGNY-UHFFFAOYSA-L 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical compound COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 2
- 229940039790 sodium oxalate Drugs 0.000 description 2
- 229960001922 sodium perborate Drugs 0.000 description 2
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- VOYADQIFGGIKAT-UHFFFAOYSA-N 1,3-dibutyl-4-hydroxy-2,6-dioxopyrimidine-5-carboximidamide Chemical compound CCCCn1c(O)c(C(N)=N)c(=O)n(CCCC)c1=O VOYADQIFGGIKAT-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical class NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 1
- CHCAGFNTASDQFX-UHFFFAOYSA-N 2-(bromomethyl)-4-fluorobenzonitrile Chemical class FC1=CC=C(C#N)C(CBr)=C1 CHCAGFNTASDQFX-UHFFFAOYSA-N 0.000 description 1
- PWINPIZUWNKSPS-UHFFFAOYSA-N 3,5-diaminobenzonitrile Chemical class NC1=CC(N)=CC(C#N)=C1 PWINPIZUWNKSPS-UHFFFAOYSA-N 0.000 description 1
- KTDRJLRJAHBQDQ-UHFFFAOYSA-N 4-amino-2-methoxybenzonitrile Chemical class COC1=CC(N)=CC=C1C#N KTDRJLRJAHBQDQ-UHFFFAOYSA-N 0.000 description 1
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical class FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
- DTALPOKFNPTJSF-UHFFFAOYSA-N 4-methoxy-3-phenylmethoxybenzonitrile Chemical class COC1=CC=C(C#N)C=C1OCC1=CC=CC=C1 DTALPOKFNPTJSF-UHFFFAOYSA-N 0.000 description 1
- ZSCUWVQXQDCSRV-UHFFFAOYSA-N 4-morpholin-4-ylbenzonitrile Chemical class C1=CC(C#N)=CC=C1N1CCOCC1 ZSCUWVQXQDCSRV-UHFFFAOYSA-N 0.000 description 1
- UYHCIOZMFCLUDP-UHFFFAOYSA-N 4-phenoxybenzonitrile Chemical class C1=CC(C#N)=CC=C1OC1=CC=CC=C1 UYHCIOZMFCLUDP-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 238000010499 C–H functionalization reaction Methods 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- FKYDBFRVTDUCBT-UHFFFAOYSA-N carbonyl dibromide manganese Chemical compound [Mn].C(=O)(Br)Br FKYDBFRVTDUCBT-UHFFFAOYSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention discloses a preparation method of deuterated aromatic nitrile compounds, which takes the aromatic nitrile compounds shown in the formula (I) as raw materials, under the protection of inert atmosphere, aryl methylimino acid ester is firstly generated in situ with aliphatic alcohol compounds in a catalytic system, then hydrogen-deuterium exchange reaction is carried out with deuteration reagent, then in situ hydrolysis is carried out to obtain aromatic nitrile ortho-position deuteration compounds, and finally, products are separated and purified; the catalytic system comprises a metal catalyst, an auxiliary agent, an oxidant and a solvent. The invention has the advantages of high operability and good deuteration effect.
Description
Technical Field
The invention relates to the technical field of synthesis of deuterated compounds, in particular to a preparation method of deuterated aromatic nitrile compounds.
Background
Deuterium is a stable form of nonradioactive isotope of hydrogen in nature, and carbon-deuterium bonds are more stable (6-9 times) than carbon-hydrogen bonds due to its greater atomic mass than hydrogen. In recent years, with research on deuterated compounds, it has been found that substitution of hydrogen in a drug molecule with deuterium can block metabolic sites and reduce the generation of toxic metabolites. Furthermore, deuteration can slow down the systemic clearance rate and thus extend the half-life of the drug in vivo. Therefore, the aim of reducing the toxic and side effects of the drug can be achieved by reducing the single administration dose while the pharmacological activity of the drug is not affected. Due to the special pharmacokinetic properties of deuterated drugs, the development speed of deuterated drugs has increased in recent years, and the demand for deuteration strategies for various active compounds has also increased.
Cyano groups have good biocompatibility and can often penetrate deep into target proteins to form hydrogen bond interaction with key amino acid residues of active sites; meanwhile, cyano can also be used as a metabolism blocking site to inhibit the oxidative metabolism of small molecules and improve the metabolic stability of the compound in vivo. As an important organic drug group, aromatic nitrile and its derivatives have been widely used in medicine and the like.
Verapamil is, for example, a calcium channel blocker for treating hypertension, angina pectoris, arrhythmia, cerebrovascular disease and the like; the febuxostat has remarkable inhibition effect on the oxidation type and the reduction type XOR, so that the effect of reducing uric acid is stronger and lasting, and the febuxostat can be used for treating chronic hyperuricemia caused by gout; itravirin is a new generation of non-nucleoside reverse transcriptase inhibitors, which can greatly reduce the morbidity and mortality of aids; pirenzenenaphthalene is commonly used for additive treatment of adult and partial seizure patients in children 12 years old and older (with or without secondary generalized seizures); the antitumor drug 2- (4-substituted piperazine-1-yl) methylbenzonitrile has stronger inhibition rate on tumor strain Skov3 (human ovarian cancer) than other tumor strains; bicalutamide is used for the treatment of advanced prostate cancer.
At present, the deuteration research on the aromatic ring of the aromatic nitrile derivative is still in the starting stage. Because the nitrile carbon-nitrogen triple bond is in a linear structure, the catalyst is difficult to form a cyclic metal transition state with nitrogen atoms and ortho-position hydrogen atoms on an aromatic ring to catalyze the reaction, and therefore, the catalyst has a great challenge for the aromatic nitrile compound ring, namely the C-H activation reaction and the H/D exchange reaction. In addition, cyano groups are a type of active functional groups in organic synthesis, can be converted into other functional groups or heterocycles, and have low tolerance to reaction conditions.
Few reports are currently made about the preparation method of deuterated aromatic nitrile derivatives. Dieter Muri et al in 2014 indirectly obtained deuterated aromatic nitrile products by deuterated amides using iridium metal complexes. The reaction needs to use deuterium as a deuterium source, and the catalyst has a complex structure and high price, so that the application range of the catalyst is greatly limited;
。
disclosure of Invention
The invention aims to provide a preparation method of deuterated aromatic nitrile compounds, which has the advantages of high operability and good deuteration effect.
The technical scheme adopted for solving the technical problems is as follows:
the preparation method of deuterated aromatic nitrile compound is characterized in that the aromatic nitrile compound shown in the formula (I) is used as a raw material, aryl methylimino acid ester is firstly generated in situ with aliphatic alcohol compounds in a catalytic system under the protection of inert atmosphere, then hydrogen-deuterium exchange reaction is carried out with deuteration reagent, then in-situ hydrolysis is carried out to obtain the aromatic nitrile ortho-deuteration compound, and finally, the product is separated and purified; the catalytic system comprises a metal catalyst, an auxiliary agent, an oxidant and a solvent;
。
the invention uses cheap metal as catalyst, uses one-pot two-step method, and has simple operation and higher hydrogen-deuterium exchange degree without separating intermediate. Has the characteristics of better operability and stability, high catalytic efficiency, high economic benefit, simple and convenient operation, easy separation of products and the like.
Preferably, the deuterated reagent is one of heavy water, deuterated methanol and deuterated benzene. More preferably heavy water.
Preferably, the inert atmosphere is a gaseous atmosphere composed of nitrogen or argon.
Preferably, the metal catalyst is selected from one of manganese decacarbonyl, manganese pentacarbonyl bromide, manganese acetate, cobalt hydroxide, ferric oxide and ferric oxide. When manganese pentacarbonyl bromide is used, the highest deuteration degree can reach 98%.
Preferably, the auxiliary agent is one of sodium acetate, potassium acetate, sodium oxalate, sodium carbonate and potassium carbonate. When sodium acetate is selected, the highest deuteration degree can reach 95%. The addition of the auxiliary agent can effectively promote the exchange rate of hydrogen and deuterium in the reaction process and improve the deuteration degree of the reaction.
Preferably, the solvent isN-one of methyl pyrrolidone, tetrahydrofuran, dioxane, cyclohexane, cyclopentyl methyl ether. Preferably N-methyl pyrrolidone, and when the solvent is selected, the highest deuteration degree of the product can reach 95 percent.
Preferably, the oxidant is one of sodium hypochlorite, hydrogen peroxide, peracetic acid, sodium dichromate, sodium perborate, potassium perborate, and methyl hypochlorite. When sodium hypochlorite is selected, the highest deuteration degree can reach 95%. The addition of the oxidant can promote the nitrile compound and the alcohol to generate aryl azomethionate in situ.
Preferably, the fatty alcohol compound is one of methanol, ethanol, isopropanol, tertiary butanol and benzyl alcohol. When ethanol is selected, the highest deuteration degree can reach 98 percent.
Preferably, the molar ratio of the materials is aromatic nitrile compound: fatty alcohol compounds: oxidizing agent: deuterated reagent: metal catalyst: auxiliary agent: solvent = 1: 1.1: 1: 10-500: 0.05-0.20:1: 20-500.
Preferably, the R 1 Is alkyl, alkoxy, vinyl, aromatic substituent, nitro, amino, triOne or more of fluoromethyl, halogen, pyridine, thiophene and furan; the R is 2 Is one or more of benzyl, methyl, ethyl, isopropyl, tertiary butyl, alkoxy, allyl and tertiary butyl. The alkyl group may be saturated hydrocarbon of 1-6 carbon atoms, cyclopropyl, cyclobutyl, cyclopentyl, cyclobutyl, etc. The aromatic substituent may be phenyl, naphthalene, etc.
The beneficial effects of the invention are as follows: according to the invention, the transition metal is utilized to activate the aromatic nitrile compound, the aryl methylimino acid ester intermediate is formed, and the deuteration reagent is taken as a deuteration source to realize the deuteration reaction of the aromatic nitrile compound, so that the synthesis of the deuteration product is realized, the operability is high, the operation is convenient, and the cost is low.
The method is completed under the condition of a conventional laboratory by adopting a technical route, the solvent does not need to be replaced halfway in the one-pot reaction, the reaction operability is high, the deuteration effect is good, the selectivity is good, and the application range is wide.
The process method has good universality, can be used for preparing deuterated products of various aromatic nitrile compounds, and is also applicable to various aromatic nitrile medicaments.
Detailed Description
The technical scheme of the invention is further specifically described by the following specific examples.
In the present invention, the materials and equipment used are commercially available or commonly used in the art, unless otherwise specified. The methods in the following examples are conventional in the art unless otherwise specified.
General embodiment
The preparation method of deuterated aromatic nitrile compound is characterized in that the aromatic nitrile compound shown in the formula (I) is used as a raw material, aryl methylimino acid ester is firstly generated in situ with aliphatic alcohol compounds in a catalytic system under the protection of inert atmosphere, then hydrogen-deuterium exchange reaction is carried out with deuteration reagent, then in-situ hydrolysis is carried out to obtain the aromatic nitrile ortho-deuteration compound, and finally, the product is separated and purified; the catalytic system comprises a metal catalyst, an auxiliary agent, an oxidant and a solvent;
;
the deuterated reagent is one of heavy water, deuterated methanol and deuterated benzene; the inert atmosphere is a gas environment formed by nitrogen or argon; the metal catalyst is selected from one of manganese decacarbonyl, manganese pentacarbonyl bromide, manganese acetate, cobalt hydroxide, ferric oxide and ferroferric oxide; the auxiliary agent is one of sodium acetate, potassium acetate, sodium oxalate, sodium carbonate and potassium carbonate; the solvent isN-one of methyl pyrrolidone, tetrahydrofuran, dioxane, cyclohexane, cyclopentyl methyl ether; the oxidant is one of sodium hypochlorite, hydrogen peroxide, peracetic acid, sodium dichromate, sodium perborate, potassium perborate and methyl hypochlorite; the fatty alcohol compound is one of methanol, ethanol, isopropanol, tertiary butanol and benzyl alcohol.
The molar usage ratio of the materials is that the aromatic nitrile compound: fatty alcohol compounds: oxidizing agent: deuterated reagent: metal catalyst: auxiliary agent: solvent = 1: 1.1: 1: 10-500: 0.05-0.20:1: 20-500.
The R is 1 Is one or more of alkyl, alkoxy, vinyl, aromatic substituent, nitro, amino, trifluoromethyl, halogen, pyridine, thiophene and furan; the R is 2 Is one or more of benzyl, methyl, ethyl, isopropyl, tertiary butyl, alkoxy, allyl and tertiary butyl.
Example 1 synthesis of benzonitrile ortho-deuterated product:
under nitrogen atmosphere, 15 mL dry sealed tube was taken, benzonitrile (103 mg, 1 mmol) and sodium hypochlorite (150 mg, 2 mmol) were added sequentially, ethanol (0.1 mL) was slowly added dropwise with stirring, and the reaction solution was reacted at room temperature for 24 hours (arylmethylimino acid ester was prepared in situ). To the reaction mixture was then added manganese carbonyl bromide (27.5 mg, 0.1 mmol), sodium acetate (82 mg, 1 mmol), N-methylpyrrolidone: heavy water=0.5/0.5 mL (v/v=1/1), and reacted at 100 ℃ for 0.5 hours. After the reaction, 5 ml of 1N aq HCl was added and stirred at room temperature for about 1 hour (hydrolysis of aryl azomethionate to give aromatic nitrile). With 10The ethyl acetate is extracted for 2 to 3 times, the organic phase is dried and concentrated to obtain a crude product. The crude product is purified by column chromatography to obtain the benzonitrile ortho-deuterated product. 1 H NMR (500 MHz, Chloroform-d)δ7.62 (m, 1H), 7.60-7.54 (m, 0.2 H), 7.49-7.47 (m, 2H)。
Under the same conditions, starting from each substituted aromatic nitrile derivative, derivative 1 (deuterated product of the aromatic nitrile derivative represented by formula II) was obtained under the above conditions, and the results are shown in the following table:
。
deuterated 4-aminophenylacetonitrile, 2-d
1 H NMR (500 MHz, Chloroform-d) δ 6.94-6.92 (m, 0.18 H, Labelled), 6.57-6.55 (m, 2H), 3.62(t, J = 1.0 Hz, 2H), 3.16 (brs, 2H).
Deuterated 4-fluorobenzonitrile, 3-d
1 H NMR (500 MHz, Chloroform-d) δ 7.61-7.57 (m, 0.2H, Labelled), 7.15-7.09 (m, 2H).
Deuterated 3, 5-diaminobenzonitrile, 4-d
1 H NMR (500 MHz, Chloroform-d) δ 6.83-6.73 (m, 0.22H, Labelled), 5.44 (s, 1H), 4.35 (brs, 4H).
Deuterated 2-bromomethyl-4-fluorobenzonitrile, 5-d
1 H NMR (500 MHz, Chloroform-d) δ 7.66-7.58 (m, 0.07H, Labelled), 7.10 (d, J = 16.5 Hz, 1H), 7.08 (m, 1H), 4.51 (d, J = 1.1 Hz, 2H).
Deuterated 4-amino-2-methoxybenzonitrile, 6-d
1 H NMR (500 MHz, Chloroform-d) δ 7.42-7.40 (m, 0.13H, Labelled), 6.42-6.37 (m, 2H), 4.40 (brs, 2H), 3.92(s, 3H).
Deuterated 4-phenoxybenzonitrile, 7-d
1 H NMR (500 MHz, Chloroform-d) δ 7.74-7.69 (m, 0.26H, Labelled), 7.37-7.32 (m, 2H), 7.18-7.13 (m, 2H), 7.09(tt, J = 9.0, 2.0 Hz, 1H), 7.03-7.01 (m, 2H).
Deuterated 4-morpholinyl benzonitrile, 8-d
1 H NMR (500 MHz, Chloroform-d) δ 7.13-7.07 (m, 0.16H, Labelled), 6.87-6.80 (m, 2H), 3.89-3.83 (m, 4H),3.19-3.13 (m, 4H).
Deuterated 3-benzyloxy-4-methoxybenzonitrile, 9-d
1 H NMR (500 MHz, Chloroform-d) δ 7.45-7.43 (m, 0.06H, Labelled), 7.40-7.37 (m, 4H), 7.35-7.34 (m, 0.11H, Labelled), 7.33-7.29 (m, 1H),7.26-7.24 (m, 1H), 5.15 (t,J= 1.0 Hz, 2H), 3.87 (s, 3H).
Deuterated febuxostat, 10-d
1 H NMR (500 MHz, Chloroform-d) δ 8.26 (d,J= 2.1 Hz, 1H), 8.19-8.17 (m, 1H), 7.22-7.20 (m, 0.1H, Labelled), 3.96 (d,J= 5.0 Hz, 2H), 2.85-2.77 (m, 1H), 2.68 (s, 3H), 1.15 (d,J= 7.2 Hz, 6H)。
The above-described embodiment is only a preferred embodiment of the present invention, and is not limited in any way, and other variations and modifications may be made without departing from the technical aspects set forth in the claims.
Claims (4)
1. A preparation method of deuterated aromatic nitrile compound is characterized in that aromatic nitrile compound shown in formula (I) is used as raw material, aryl methylimino acid ester is generated with aliphatic alcohol compound in situ in a catalytic system under the protection of inert atmosphere, then hydrogen-deuterium exchange reaction is carried out with deuteration reagent, then in-situ hydrolysis is carried out to obtain aromatic nitrile ortho-deuteration compound, and finally, the product is separated and purified; the catalytic system comprises a metal catalyst, an auxiliary agent, an oxidant and a solvent;
;
the metal catalyst is selected from one of manganese decacarbonyl, manganese pentacarbonyl bromide and manganese acetate;
the saidThe oxidant is sodium hypochlorite; the fatty alcohol compound is one of methanol, ethanol, isopropanol, tertiary butanol and benzyl alcohol; the molar usage ratio of the materials is that the aromatic nitrile compound: fatty alcohol compounds: oxidizing agent: deuterated reagent: metal catalyst: auxiliary agent: solvent = 1: 1.1: 1: 10-500: 0.05-0.20:1: 20-500; the R is 1 Is one or more of alkyl, alkoxy, vinyl, nitro, amino, trifluoromethyl, halogen, pyridine, thiophene and furan.
2. The method of claim 1, wherein the deuterating agent is one of heavy water, deuterated methanol, deuterated benzene.
3. The method according to claim 1, wherein the inert atmosphere is a gaseous atmosphere composed of nitrogen or argon.
4. The method according to claim 1, wherein the solvent isN-one of methyl pyrrolidone, tetrahydrofuran, dioxane, cyclohexane, cyclopentyl methyl ether.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210812275.XA CN115215764B (en) | 2022-07-11 | 2022-07-11 | Preparation method of deuterated aromatic nitrile compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210812275.XA CN115215764B (en) | 2022-07-11 | 2022-07-11 | Preparation method of deuterated aromatic nitrile compound |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115215764A CN115215764A (en) | 2022-10-21 |
CN115215764B true CN115215764B (en) | 2023-12-08 |
Family
ID=83612052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210812275.XA Active CN115215764B (en) | 2022-07-11 | 2022-07-11 | Preparation method of deuterated aromatic nitrile compound |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115215764B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0782252A (en) * | 1993-06-30 | 1995-03-28 | Fuji Photo Film Co Ltd | Production of imidic acid ester compound and n-pyrazolylamidoxime compound |
CN104529823A (en) * | 2014-10-23 | 2015-04-22 | 江苏南方农药研究中心 | Benzimidate compound preparation method |
CN108675942A (en) * | 2018-06-19 | 2018-10-19 | 杭州盛漫生物科技有限公司 | A kind of preparation method of aromatic nitrile compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220024925A1 (en) * | 2020-07-22 | 2022-01-27 | Acurx Pharmaceuticals Llc | Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof |
-
2022
- 2022-07-11 CN CN202210812275.XA patent/CN115215764B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0782252A (en) * | 1993-06-30 | 1995-03-28 | Fuji Photo Film Co Ltd | Production of imidic acid ester compound and n-pyrazolylamidoxime compound |
CN104529823A (en) * | 2014-10-23 | 2015-04-22 | 江苏南方农药研究中心 | Benzimidate compound preparation method |
CN108675942A (en) * | 2018-06-19 | 2018-10-19 | 杭州盛漫生物科技有限公司 | A kind of preparation method of aromatic nitrile compounds |
Non-Patent Citations (2)
Title |
---|
Manganese-Catalyzed ortho-C-H Alkenylation of Aromatic N-H Imidates with Alkynes: Versatile Access to Mono-Alkenylated Aromatic Nitriles.;Xiaoxu Yang,et al.;《Adv. Synth. Catal.》;第358卷;2436- 2442 * |
Manganese-catalyzed selective C–H activation and deuteration by means of a catalytic transient directing group strategy;Sara Kopf,et al.;《Chem. Commun.》;第57卷;1137-1140 * |
Also Published As
Publication number | Publication date |
---|---|
CN115215764A (en) | 2022-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20170117027A (en) | Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives | |
Ni et al. | A convenient access to allylic triflones with allenes and triflyl chloride in the presence of (EtO) 2P (O) H | |
CN115215764B (en) | Preparation method of deuterated aromatic nitrile compound | |
CN108794412B (en) | Preparation method of 4, 5-diaryl-2H-1, 2, 3-triazole compound | |
Qian et al. | Electrochemical oxythiocyanation of ortho-olefinic amides: Access to diverse thiocyanated benzoxazines | |
CN112301370B (en) | Electrochemical synthesis method of 1, 3-dimethyl-3-difluoroethyl-2-oxindole compound | |
Zhang et al. | Iron/TEMPO-catalyzed direct aerobic oxidative coupling of methyl-mubstituted N-heteroazaarenes with alcohols | |
CN107118215B (en) | A kind of preparation method for treating breast cancer medicines Rui Boxini intermediate | |
CN111747858B (en) | Method for constructing C-N bond through insertion reaction of nonmetal-catalyzed sulfur ylide and aromatic amine and application | |
CN110483346B (en) | Sulfonyl-substituted alpha-cyclopropylstyrene compound and synthesis method thereof | |
KR20140042805A (en) | Intermediate for synthesizing caspofungin and preparation method therefor | |
JP2009029733A (en) | METHOD FOR PRODUCING alpha,beta-UNSATURATED CARBONYL COMPOUND | |
Zhou et al. | New conformationally flexible and recyclable aryl iodine catalysts from an inexpensive chiral source for asymmetric oxidations | |
CN109369514A (en) | A kind of synthetic method of six-membered carbon ring derivative | |
CN113754605A (en) | Nitrogen-containing ligand and preparation method and application thereof | |
CN110845363A (en) | O-alkenyl aromatic nitrile compound and preparation method thereof | |
CN115286547B (en) | Method for synthesizing aryl benzyl thioether compound | |
CN110627723A (en) | Trifluoromethyl pyrazole derivative and application thereof | |
CN105820096B (en) | A kind of method for preparing substitution ethyl aryl sulfone | |
CN113277935B (en) | Far-end halogenated alkyl ketone using HX as halogen source and synthesis method thereof | |
Saegusa et al. | Bromocyclization of Unsaturated Thioester and Access to Functionalized Sulfur-heterocycles | |
CN111635372B (en) | Oxazolone derivative and synthetic method thereof | |
JP2014148477A (en) | Reaction method and novel azo compound used in the same | |
CN115710199B (en) | Photooxidation reduction catalytic process | |
CN112920129B (en) | 1,2, 3-triazole-2-oxide and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |